Magellan Health (MGLN) quarterly balance sheet covering the six quarters from June 2020 to September 2021, as reported to the SEC.
A balance sheet shows what a company owns and what it owes on a single date. The difference between the two belongs to shareholders.
| Sep'21 | Jun'21 | Mar'21 | Dec'20 | Sep'20 | Jun'20 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets [Abstract] | |||||||||||||||||||||
Current Assets: | |||||||||||||||||||||
Cash and cash equivalents ($49,227 and $79,746 restricted at December 31, 2020 and September 30, 2021, respectively) | |||||||||||||||||||||
1,038 | 678 | 456 | 1,144 | 152 | 160 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Cash and cash equivalents ($49,227 and $79,746 restricted at December 31, 2020 and September 30, 2021, respectively) | 1,038 | 678 | 456 | 1,144 | 152 | 160 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Restricted cash | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Restricted cash | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Accounts receivable, net | |||||||||||||||||||||
827 | 826 | 793 | 743 | 769 | 753 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Accounts receivable, net | 827 | 826 | 793 | 743 | 769 | 753 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Short-term investments ($88,867 and $101,884 restricted at December 31, 2020 and September 30, 2021, respectively) | |||||||||||||||||||||
155 | 325 | 625 | 140 | 92 | 75 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Short-term investments ($88,867 and $101,884 restricted at December 31, 2020 and September 30, 2021, respectively) | 155 | 325 | 625 | 140 | 92 | 75 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Deferred income taxes | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Deferred income taxes | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Pharmaceutical inventory | |||||||||||||||||||||
39 | 38 | 46 | 43 | 37 | 36 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Pharmaceutical inventory | 39 | 38 | 46 | 43 | 37 | 36 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other current assets ($43,547 and $74,385 restricted at December 31, 2020 and September 30, 2021, respectively) | |||||||||||||||||||||
143 | 145 | 101 | 84 | 95 | 80 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Other current assets ($43,547 and $74,385 restricted at December 31, 2020 and September 30, 2021, respectively) | 143 | 145 | 101 | 84 | 95 | 80 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Current portion of assets held for sale | |||||||||||||||||||||
- | - | - | - | 1,144 | 1,145 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Current portion of assets held for sale | - | - | - | - | 1,144 | 1,145 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total Current Assets | |||||||||||||||||||||
2,204 | 2,015 | 2,023 | 2,156 | 2,291 | 2,252 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total Current Assets | 2,204 | 2,015 | 2,023 | 2,156 | 2,291 | 2,252 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Property and equipment, net | |||||||||||||||||||||
137 | 141 | 142 | 136 | 131 | 141 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Property and equipment, net | 137 | 141 | 142 | 136 | 131 | 141 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Long-term investments ($1,026 and $0 restricted at December 31, 2020 and September 30, 2021, respectively) | |||||||||||||||||||||
- | 2 | 4 | 2 | 5 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Long-term investments ($1,026 and $0 restricted at December 31, 2020 and September 30, 2021, respectively) | - | 2 | 4 | 2 | 5 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Deferred income taxes | |||||||||||||||||||||
- | - | 0 | 1 | 25 | 28 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Deferred income taxes | - | - | 0 | 1 | 25 | 28 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other long-term assets | |||||||||||||||||||||
81 | 120 | 119 | 108 | 67 | 60 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Other long-term assets | 81 | 120 | 119 | 108 | 67 | 60 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Goodwill | |||||||||||||||||||||
873 | 873 | 873 | 873 | 806 | 806 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Goodwill | 873 | 873 | 873 | 873 | 806 | 806 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other intangible assets, net | |||||||||||||||||||||
57 | 64 | 71 | 79 | 52 | 62 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Other intangible assets, net | 57 | 64 | 71 | 79 | 52 | 62 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Assets held for sale, less current portion | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Assets held for sale, less current portion | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total Assets | |||||||||||||||||||||
3,353 | 3,217 | 3,236 | 3,359 | 3,381 | 3,351 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total Assets | 3,353 | 3,217 | 3,236 | 3,359 | 3,381 | 3,351 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY | |||||||||||||||||||||
Current Liabilities: | |||||||||||||||||||||
Accounts payable | |||||||||||||||||||||
171 | 132 | 149 | 137 | 122 | 99 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Accounts payable | 171 | 132 | 149 | 137 | 122 | 99 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Accrued liabilities | |||||||||||||||||||||
231 | 208 | 266 | 354 | 235 | 187 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Accrued liabilities | 231 | 208 | 266 | 354 | 235 | 187 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Short-term contingent consideration | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Short-term contingent consideration | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Medical claims payable | |||||||||||||||||||||
187 | 147 | 116 | 111 | 119 | 112 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Medical claims payable | 187 | 147 | 116 | 111 | 119 | 112 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other medical liabilities | |||||||||||||||||||||
162 | 138 | 123 | 126 | 123 | 110 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Other medical liabilities | 162 | 138 | 123 | 126 | 123 | 110 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Current debt, finance lease and deferred financing obligations | |||||||||||||||||||||
3 | 3 | 6 | 6 | 4 | 84 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Current debt, finance lease and deferred financing obligations | 3 | 3 | 6 | 6 | 4 | 84 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Current portion of liabilities held for sale | |||||||||||||||||||||
- | - | - | - | 496 | 504 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Current portion of liabilities held for sale | - | - | - | - | 496 | 504 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total Current Liabilities | |||||||||||||||||||||
756 | 629 | 662 | 737 | 1,100 | 1,098 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total Current Liabilities | 756 | 629 | 662 | 737 | 1,100 | 1,098 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Long-term debt, finance lease and deferred financing obligations | |||||||||||||||||||||
516 | 521 | 526 | 631 | 637 | 641 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Long-term debt, finance lease and deferred financing obligations | 516 | 521 | 526 | 631 | 637 | 641 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Deferred income taxes | |||||||||||||||||||||
18 | 17 | 13 | 7 | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Deferred income taxes | 18 | 17 | 13 | 7 | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Tax contingencies | |||||||||||||||||||||
12 | 12 | 11 | 11 | 11 | 11 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Tax contingencies | 12 | 12 | 11 | 11 | 11 | 11 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Long-term contingent consideration | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Long-term contingent consideration | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Deferred credits and other long-term liabilities | |||||||||||||||||||||
76 | 78 | 79 | 69 | 52 | 56 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Deferred credits and other long-term liabilities | 76 | 78 | 79 | 69 | 52 | 56 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Liabilities held for sale, less current portion | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Liabilities held for sale, less current portion | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total Liabilities | |||||||||||||||||||||
1,380 | 1,260 | 1,293 | 1,456 | 1,801 | 1,808 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total Liabilities | 1,380 | 1,260 | 1,293 | 1,456 | 1,801 | 1,808 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Redeemable non-controlling interest | |||||||||||||||||||||
39 | 33 | 33 | 33 | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Redeemable non-controlling interest | 39 | 33 | 33 | 33 | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Stockholder's Equity: | |||||||||||||||||||||
Preferred stock, par value $.01 per share Authorized-10,000 shares at December 31, 2020 and September 30, 2021-Issued and outstanding-none | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Preferred stock, par value $.01 per share Authorized-10,000 shares at December 31, 2020 and September 30, 2021-Issued and outstanding-none | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Common stock, par value $.01 per share: Authorized-100,000 shares at December 31, 2020 and September 30, 2021-Issued and outstanding-55,549 and 25,887 shares at December 31, 2020, respectively, and 55,994 and 26,332 shares at September 30, 2021, respectively | |||||||||||||||||||||
0 | 0 | 0 | 0 | 0 | 0 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Common stock, par value $.01 per share: Authorized-100,000 shares at December 31, 2020 and September 30, 2021-Issued and outstanding-55,549 and 25,887 shares at December 31, 2020, respectively, and 55,994 and 26,332 shares at September 30, 2021, respectively | 0 | 0 | 0 | 0 | 0 | 0 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other Stockholders' Equity: | |||||||||||||||||||||
Additional paid-in capital | |||||||||||||||||||||
1,512 | 1,503 | 1,488 | 1,477 | 1,455 | 1,429 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Additional paid-in capital | 1,512 | 1,503 | 1,488 | 1,477 | 1,455 | 1,429 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Retained earnings | |||||||||||||||||||||
1,885 | 1,884 | 1,884 | 1,857 | 1,588 | 1,576 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Retained earnings | 1,885 | 1,884 | 1,884 | 1,857 | 1,588 | 1,576 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Warrants outstanding | |||||||||||||||||||||
- | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Warrants outstanding | - | - | - | - | - | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Accumulated other comprehensive loss | |||||||||||||||||||||
-0 | -0 | -0 | -0 | 0 | 0 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Accumulated other comprehensive loss | -0 | -0 | -0 | -0 | 0 | 0 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Treasury stock, at cost, 29,662 and 29,662 shares at December 31, 2020 and September 30, 2021, respectively | |||||||||||||||||||||
1,464 | 1,464 | 1,464 | 1,464 | 1,464 | 1,464 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Treasury stock, at cost, 29,662 and 29,662 shares at December 31, 2020 and September 30, 2021, respectively | 1,464 | 1,464 | 1,464 | 1,464 | 1,464 | 1,464 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total Stockholders' Equity | |||||||||||||||||||||
1,933 | 1,923 | 1,909 | 1,869 | 1,579 | 1,542 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total Stockholders' Equity | 1,933 | 1,923 | 1,909 | 1,869 | 1,579 | 1,542 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total Liabilities, Redeemable Non-Controlling Interest and Stockholders' Equity | |||||||||||||||||||||
3,353 | 3,217 | 3,236 | 3,359 | 3,381 | 3,351 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total Liabilities, Redeemable Non-Controlling Interest and Stockholders' Equity | 3,353 | 3,217 | 3,236 | 3,359 | 3,381 | 3,351 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||